...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung.
【24h】

Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung.

机译：表皮生长因子受体基因突变定义不同的子集之间的小肺腺癌。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Epidermal growth factor receptor (EGFR) gene mutations are frequently detected in lung cancer, especially in adenocarcinoma, in females, and non-smoking patients. EGFR mutations are closely associated with clinical response to EGFR tyrosine kinase inhibitor. Bronchioloalveolar carcinoma (BAC) appearance is a good predictor of response to this agent. Noguchi et al. subdivided small peripheral adenocarcinoma of the lung into two groups. One group was characterized with tumor cell growth replacing the normal alveolar cells with varying degree of fibrosis (types A-C), and the other shows non-replacing and destructive growth (types D-F). Using probes for the 13 mutations which have been previously described, we have genotyped the EGFR gene status in surgically resected atypical adenomatous hyperplasias (AAH) and small peripheral adenocarcinomas up to 2 cm in diameter using TaqMan PCR assay. In 95 small-sized adenocarcinomas, the EGFR mutations were detected in 37 patients (38.9%), and no mutations were found in five AAHs. In small peripheral adenocarcinomas, EGFR mutations were found 47.1% of types A, B, or C adenocarcinomas; it was less frequent (16%) in Noguchi's types D, E or F adenocarcinomas. These results suggest that type D, F adenocarcinomas are not derived from the less malignant types A-C adenocarcinomas; rather, they have arisen de novo by distinct mechanisms. Although types A and B adenocarcinomas are almost 100% cured by surgery, some type C adenocarcinoma show lymph node metastasis and relapse. EGFR mutation analysis may help identify patients who will respond to treatment with tyrosine kinase inhibitors, e.g., gefitinib.
机译：表皮生长因子受体(EGFR)基因突变经常在肺癌中发现,特别是在腺癌、女性和不吸烟的病人。表皮生长因子受体与临床相关的反应酪氨酸激酶抑制剂。癌(BAC)的外观是一个很好的预测应对这个代理。小外围肺腺癌两组。肿瘤细胞生长取代了正常的肺泡细胞有不同程度的纤维化(类型a - c)和其他显示non-replacing和D-F破坏性增长(类型)。之前的13个突变描述,我们有表皮生长因子受体基因的基因状况在手术切除非典型腺瘤增生(啊)和小外围腺癌,直径2厘米TaqMan PCR分析。腺癌,表皮生长因子受体突变检测37例(38.9%),没有突变发现五兴奋。腺癌,表皮生长因子受体突变被发现47.1%类型的A、B或C腺癌;频繁(16%)在野口的类型D, E和F腺癌。D, F腺癌并不来自于少得了恶性肿瘤类型腺癌;他们出现新创通过不同的机制。尽管A型和B型腺癌几乎100%通过手术治愈,一些C型腺癌显示淋巴结转移和复发。突变分析可以帮助确定病人和酪氨酸激酶反应治疗吗抑制剂,例如,吉非替尼。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号